Sensitive Voltammetric Method for Rapid Determination of Sarcosine as a New Biomarker for Prostate Cancer Using a TiO2 Nanoparticle/Ionic Liquid Modified Carbon Paste Electrode

Bahrami, Hengameh; Mousavi, Mehdi; Maghsoudi, Shahab

doi:10.1134/s1023193521020099

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18,19] Strong evidence suggests that the profile of SAR could effectively differentiate benign prostate, localized, and metastatic PCa. [20] In light of the clinical view, elevated PSA and SAR levels in the blood are linked to a greater risk of PCa. In particular, elevated SAR levels can be used to diagnose PCa in the gray zone.…”

Section: Introductionmentioning

confidence: 99%

Portable and Rapid Dual‐Biomarker Detection Using Solution‐Gated Graphene Field Transistors in the Accurate Diagnosis of Prostate Cancer

Deng,

Yang,

Zhang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Prostate‐specific antigen (PSA) is the common serum‐relevant biomarker for early prostate cancer (PCa) detection in clinical diagnosis. However, it is difficult to accurately diagnose PCa in the early stage due to the low specificity of PSA. Herein, a new solution‐gated graphene field transistor (SGGT) biosensor with dual‐gate for dual‐biomarker detection is designed. The sensing mechanism is that the designed aptamers immobilized on the surface of the gate electrodes can capture PSA and sarcosine (SAR) biomolecules and induce the capacitance changes of the electric double layers of SGGT. The limit of detections of PSA and SAR biomarkers can reach 0.01 fg mL−1, which is three‐to‐four orders of magnitude lower than previously reported assays. The detection time of PSA and SAR is ≈4.5 and ≈13 min, which is significantly faster than the detection time (1–2 h) of conventional methods. The clinical serum samples testing demonstrates that the biosensor can distinguish the PCa patients from the control group and the diagnosis accuracy can reach 100%. The SGGT biosensor can be integrated into the portable platform and the diagnostic results can directly display on the smartphone/Pad. Therefore, the integrated portable platform of the biosensor can distinguish cancer types through the dual‐biomarker detection.

show abstract

Section: Introductionmentioning

confidence: 99%

Portable and Rapid Dual‐Biomarker Detection Using Solution‐Gated Graphene Field Transistors in the Accurate Diagnosis of Prostate Cancer

Deng,

Yang,

Zhang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

Development of a sensitive voltammetric sensor for diltiazem determination in biological samples using MWCNT/PPy-PBA modified glassy carbon electrode

2021

View full text Add to dashboard Cite

Non-enzymatic electrochemical detection of sarcosine in serum of prostate cancer patients by CoNiWBO/rGO nanocomposite

Wasim,

Shaheen,

Fatima

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Selective and sensitive sarcosine detection is crucial due to its recent endorsement as a prostate cancer (PCa) biomarker in clinical diagnosis. The reduced graphene oxide-cobalt nickel tungsten boron oxides (CoNiWBO/rGO) nanocomposite is developed as a non-enzymatic electrochemical sensor for sarcosine detection in PCa patients’ serum. CoNiWBO/rGO is synthesized by the chemical reduction method via a one-pot reduction method followed by calcination at 500 °C under a nitrogen environment for 2 h and characterized by UV-Vis, XRD, TGA, and SEM. CoNiWBO/rGO is then deposited on a glassy carbon electrode, and sarcosine sensing parameters are optimized, including concentration and pH. This non-enzymatic sensor is employed to directly determine sarcosine in serum samples. Differential pulse voltammetry (DPV) and linear sweep voltammetry (LSV) are employed to monitor the electrochemical behavior where sarcosine binding leads to oxidation. Chronoamperometric studies show the stability of the developed sensor. The results demonstrate a wide linear range from 0.1 to 50 µM and low limits of detection, i.e., 0.04 µM and 0.07 µM using DPV and LSV respectivel. Moreover, the calculated recovery of sarcosine in human serum of prostate cancer patients is 78–96%. The developed electrochemical sensor for sarcosine detection can have potential applications in clinical diagnosis.

show abstract

Sensitive Voltammetric Method for Rapid Determination of Sarcosine as a New Biomarker for Prostate Cancer Using a TiO2 Nanoparticle/Ionic Liquid Modified Carbon Paste Electrode

Cited by 3 publications

References 33 publications

Portable and Rapid Dual‐Biomarker Detection Using Solution‐Gated Graphene Field Transistors in the Accurate Diagnosis of Prostate Cancer

Portable and Rapid Dual‐Biomarker Detection Using Solution‐Gated Graphene Field Transistors in the Accurate Diagnosis of Prostate Cancer

Development of a sensitive voltammetric sensor for diltiazem determination in biological samples using MWCNT/PPy-PBA modified glassy carbon electrode

Non-enzymatic electrochemical detection of sarcosine in serum of prostate cancer patients by CoNiWBO/rGO nanocomposite

Contact Info

Product

Resources

About